The pharmacokinetics of oral rivaroxaban are highly predictable and only affected to a
limited extent by bodyweight; therefore, dose adjustments for bodyweight are not required …

Venous thromboembolism (VTE) is a leading cause of morbidity and mortality worldwide.
Appropriate anticoagulation is crucial in the treatment and prevention of recurrent VTE …

Essentials• The optimal dosing strategy of rivaroxaban for patients at the extremes of body
weight is not known.• A pharmacokinetic study was conducted based in real‐world patients …

Over recent years, research on anticoagulant drugs has been guided by the requirement for
convenient administration and a wide therapeutic window to allow fixed dosing without the …

Patients with deep vein thrombosis or pulmonary embolism are recommended to receive
anticoagulation for acute treatment and secondary prevention of venous thromboembolism …

The study aim was to identify predictive factors for major bleeding in patients receiving the
novel oral factor Xa inhibitor rivaroxaban or enoxaparin-vitamin K antagonists (VKAs) for the …

There is limited data evaluating clinical outcomes of rivaroxaban versus warfarin in obese
patients with venous thromboembolism (VTE). Our objective was to evaluate the …

Rivaroxaban (Xarelto®), an oral direct factor Xa inhibitor, is approved for the initial treatment
of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as the prevention of …

We investigated three-month clinical outcomes in patients with venous thromboembolism
(VTE) treated with rivaroxaban or conventional anticoagulation in routine clinical practice …

Background Rivaroxaban is a new oral anticoagulant (NOAC) that can be prescribed in a
fixed dose, making regular monitoring and dose adjustments unnecessary. It has been …